Sana Biotechnology (SANA), a clinical-stage biotech company specializing in gene and cell therapies, has recently experienced significant moves in its stock performance, attracting investor attention.

周三， Sana Biotechnology(SANA.US)暴涨超232%，报5.52美元。消息面上，Sana 生物技术发布了其在研治疗 1 型糖尿病的积极数据。该公司表示，它将其治疗UP421 ...

Sana’s HIP technology aims to eliminate the ... In three months, CytomX Therapeutics’ stock has lost 14.5%. CTMX’s earnings beat estimates in two of the trailing four quarters and missed ...

Sana Biotechnology (SANA) stock soared after the company announced what it believes is a world-first breakthrough for type-1 diabetes treatments. Shares of SANA were up about 400% at one stage ...

Shares of Sana Biotechnology SANA skyrocketed 151.5% in the past week after the company announced positive initial results from a potentially groundbreaking type 1 diabetes (T1D) study of its ...

On Tuesday, H.C. Wainwright analyst Emily Bodnar increased the price target for Sana Biotechnology (NASDAQ:SANA) shares to $11 from the previous $8, while maintaining a Buy rating on the stock.